BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25762634)

  • 1. MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).
    Zhang J; Wang Y; Chen X; Zhou Y; Jiang F; Chen J; Wang L; Zhang WF
    Oncotarget; 2015 Apr; 6(10):7454-69. PubMed ID: 25762634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.
    Kumar B; Yadav A; Lang J; Teknos TN; Kumar P
    PLoS One; 2012; 7(5):e37601. PubMed ID: 22629428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-34a suppresses HNSCC growth through modulating cell cycle arrest and senescence.
    Wang Y; Chen J; Chen X; Jiang F; Sun Y; Pan Y; Zhang W; Zhang J
    Neoplasma; 2017; 64(4):543-553. PubMed ID: 28485160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.
    Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Matsushita R; Mataki H; Mizuno K; Okamoto Y; Seki N
    J Hum Genet; 2017 Jan; 62(1):113-121. PubMed ID: 27169691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-141 suppresses growth and metastatic potential of head and neck squamous cell carcinoma.
    Zhao Z; Gao D; Ma T; Zhang L
    Aging (Albany NY); 2019 Feb; 11(3):921-932. PubMed ID: 30737360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA profile in site-specific head and neck squamous cell cancer.
    Kalfert D; Pesta M; Kulda V; Topolcan O; Ryska A; Celakovsky P; Laco J; Ludvikova M
    Anticancer Res; 2015 Apr; 35(4):2455-63. PubMed ID: 25862914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting Flotillin-2.
    Li X; Zhao S; Fu Y; Zhang P; Zhang Z; Cheng J; Liu L; Jiang H
    Int J Biol Sci; 2021; 17(15):4327-4339. PubMed ID: 34803501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
    Zhang M; Piao L; Datta J; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
    Mol Cancer Ther; 2015 Oct; 14(10):2313-20. PubMed ID: 26227488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma.
    Zhao Y; Ling Z; Hao Y; Pang X; Han X; Califano JA; Shan L; Gu X
    Oncotarget; 2017 Apr; 8(15):25005-25020. PubMed ID: 28212569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of HOXB9 and miR-196a in head and neck squamous cell carcinoma.
    Darda L; Hakami F; Morgan R; Murdoch C; Lambert DW; Hunter KD
    PLoS One; 2015; 10(4):e0122285. PubMed ID: 25860510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.
    Liu CJ; Shen WG; Peng SY; Cheng HW; Kao SY; Lin SC; Chang KW
    Int J Cancer; 2014 Feb; 134(4):811-21. PubMed ID: 23824713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-512-5p suppresses tumor growth by targeting hTERT in telomerase positive head and neck squamous cell carcinoma in vitro and in vivo.
    Li J; Lei H; Xu Y; Tao ZZ
    PLoS One; 2015; 10(8):e0135265. PubMed ID: 26258591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
    Wu X; Cheng YL; Matthen M; Yoon A; Schwartz GK; Bala S; Taylor AM; Momen-Heravi F
    J Exp Clin Cancer Res; 2021 Feb; 40(1):70. PubMed ID: 33596979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressive microRNA-133a regulates novel targets: moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma.
    Kinoshita T; Nohata N; Fuse M; Hanazawa T; Kikkawa N; Fujimura L; Watanabe-Takano H; Yamada Y; Yoshino H; Enokida H; Nakagawa M; Okamoto Y; Seki N
    Biochem Biophys Res Commun; 2012 Feb; 418(2):378-83. PubMed ID: 22266319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44.
    Zuo J; Zhu K; Wang Y; Yu Z
    Mol Cell Biochem; 2018 Jun; 443(1-2):139-149. PubMed ID: 29094237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
    Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
    Koshizuka K; Hanazawa T; Kikkawa N; Katada K; Okato A; Arai T; Idichi T; Osako Y; Okamoto Y; Seki N
    Auris Nasus Larynx; 2018 Aug; 45(4):854-865. PubMed ID: 29233721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
    Wen Y; Li H; Zeng Y; Wen W; Pendleton KP; Lui VW; Egloff AM; Grandis JR
    Oncotarget; 2016 Apr; 7(17):23300-11. PubMed ID: 27004400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.